Institute of Biomedicine/Medical Biochemistry, University of Eastern Finland, Kuopio, FI-70211 Kuopio, Finland.
Curr Opin Pharmacol. 2011 Aug;11(4):326-31. doi: 10.1016/j.coph.2011.04.006. Epub 2011 Apr 29.
FK506 binding protein 51 (FKBP51, FKBP5) functions as a co-chaperone for androgen, glucocorticoid, mineralocorticoid and progesterone receptors. The FKBP51 can act as an important determinant of the responses to steroids, especially to glucocorticoids in stress and mood disorders and androgens in prostate cancer, raising medical and pharmacological interests in the protein and its gene. Recent studies have revealed the molecular mechanisms by which the androgens and the glucocorticoids via their nuclear receptors elicit the robust up-regulation of the FKBP51 gene. Several polymorphisms in the FKBP51 gene have been associated with the mood disorders and differences in glucocorticoid sensitivity. The polymorphisms may contribute to the steroid up-regulation of the FKBP51 and thus influence the regulatory loops in steroid signaling.
FK506 结合蛋白 51（FKBP51，FKBP5）作为雄激素、糖皮质激素、盐皮质激素和孕激素受体的共伴侣蛋白发挥作用。FKBP51 可以作为对类固醇反应的重要决定因素，特别是在应激和情绪障碍中的糖皮质激素和前列腺癌中的雄激素中，这引起了人们对该蛋白及其基因的医学和药理学兴趣。最近的研究揭示了雄激素和糖皮质激素通过其核受体引发 FKBP51 基因强烈上调的分子机制。FKBP51 基因的几个多态性与情绪障碍和糖皮质激素敏感性的差异有关。这些多态性可能导致 FKBP51 的类固醇上调，从而影响类固醇信号转导中的调节环。
